Thurston Arthritis Research Center
Thurston Arthritis Research Center
Billard M.J.,Thurston Arthritis Research Center |
Timoshchenko R.G.,Thurston Arthritis Research Center |
McGinnis M.W.,Thurston Arthritis Research Center |
Foreman O.,The Jackson Laboratory |
And 3 more authors.
Molecular Immunology | Year: 2013
Polymorphism at the GPSM3 gene locus is inversely associated with four systemic autoimmune diseases, including rheumatoid arthritis and ankylosing spondylitis. G-protein signaling modulator-3 (GPSM3) expression is most pronounced in myeloid cells, in which it targets heterotrimeric G-protein Gαi subunits of chemokine receptors, critical to immune function. To begin to explore the regulatory role of GPSM3 in monocytes, human THP-1 and primary mouse myeloid cells were cultured under stimulus conditions; GPSM3 was found by immunoblotting to be expressed at highest levels in the mature monocyte. To evaluate the effects of GPSM3 deficiency on a myeloid-dependent autoimmune disease, collagen antibody-induced arthritis (CAIA) was induced in Gpsm3-/- and control mice, which were then analyzed for clinical score, paw swelling, intra-articular proinflammatory markers, and histopathology. Mice lacking GPSM3 were protected from CAIA, and expression of monocyte-representative pro-inflammatory chemokine receptors and cytokines in paws of Gpsm3-/- mice were decreased. Flow cytometry, apoptosis, and transwell chemotaxis experiments were conducted to further characterize the effect of GPSM3 deficiency on survival and chemokine responsiveness of monocytes. GPSM3-deficient myeloid cells had reduced migration ex vivo to CCL2, CX3CL1, and chemerin and enhanced apoptosis in vitro. Our results suggest that GPSM3 is an important regulator of monocyte function involving mechanisms of differentiation, survival, and chemotaxis, and deficiency in GPSM3 expression is protective in acute inflammatory arthritis. © 2012 Elsevier Ltd.
News Article | December 6, 2016
CHAPEL HILL, NC, December 06, 2016-- Dr. John Winfield has been included in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.As a rheumatologist, scientist, and educator, Dr. Winfield has spent nearly five decades diagnosing and treating arthritis and other diseases of the joints, muscles, and bones. Recognized as a diplomate by the American Board of Internal Medicine, he is also an award-winning professor who has made tremendous strides in preparing the next generation of rheumatologists and immunologists to position themselves for success. Over the course of his career at the University of North Carolina at Chapel Hill, Dr. Winfield served as Chief of the Division of Rheumatology and Immunology, was the Founding Director of the Thurston Arthritis Research Center at that institution, , and was a senior member of the Neurosensory Disorders Center of the UNC School of Dentistry. During the Vietnam War, Dr. Winfield excelled as a Senior Assistant Surgeon in the U.S. Public Health Service and conducted laboratory research as a Staff Associate in the National Institute of Allergy and Infectious Diseases at the National Institutes of Health in Bethesda, Maryland.To prepare for his career, Dr. Winfield earned a Bachelor of Arts from Williams College and an MD from Cornell University. He completed an internship in Medicine at New York Hospital, as well as a residency in Medicine and Fellowship in Rheumatology at the University of Virginia School of Medicine. To round out his skillset, Dr. Winfield went on to complete a Fellowship in Immunology in the laboratory of Dr. Henry Kunkel at Rockefeller University in New York. To remain at the top of his field, he has been an active participant in his professional community. Dr. Winfield is a fellow of the American College of Physicians and member of the American Association of Immunologists, the American Federation of Clinical Research, the American Society of Clinical Investigation, the Association of American Physicians, the American Clinical and Climatologic Association, the American College of Rheumatology and the National Society of Clinical Rheumatologists.In recognition of professional excellence, Dr. Winfield was named the Herman and Louise Smith Distinguished Professor of Medicine at the University of North Carolina at Chapel Hill, was the recipient of the Borden Prize from Cornell University Medical College, received a Senior Investigator Award from the Arthritis Foundation, a National Institutes of Health Merit Award, and was named a Master of the American College of Rheumatology. Additionally, he was the recipient of numerous research grants from the National Institutes of Health and the Arthritis Foundation. Most recently, Dr. Winfield was honored by Who's Who in America, Who's Who in Medicine and Healthcare, Who's Who in Science and Engineering, Who's Who in the South and Southwest, and Who's Who in the World.As he looks to the future, Dr. Winfield intends to continue working as an educator in the field of rheumatology.About Marquis Who's Who :Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America , Marquis Who's Who has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Today, Who's Who in America remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. Marquis now publishes many Who's Who titles, including Who's Who in America , Who's Who in the World , Who's Who in American Law , Who's Who in Medicine and Healthcare , Who's Who in Science and Engineering , and Who's Who in Asia . Marquis publications may be visited at the official Marquis Who's Who website at www.marquiswhoswho.com
Golightly Y.M.,University of North Carolina at Chapel Hill |
Allen K.D.,Duke University |
Helmick C.G.,Centers for Disease Control and Prevention |
Schwartz T.A.,Thurston Arthritis Research Center |
And 3 more authors.
Journal of Rheumatology | Year: 2010
Objective. To examine the hazard of incident and progressive radiographic osteoarthritis (rOA) and chronic joint symptoms at the hip and knee by limb length inequality (LLI) in a large, community-based sample. Methods. A longitudinal cohort completed baseline (1991-97) clinical evaluation and identical followup assessment (1999-2003) (median followup time 5.9 yrs, range 3.0-13.1 yrs). LLI was defined at baseline as a measured difference between limbs ≥ 2 cm. The study groups with LLI data comprised 1583 participants with paired (baseline and followup) knee radiographs and 1453 participants with paired hip radiographs. Multivariable Cox regression models were used to examine the hazard of incident and progressive knee and hip rOA and chronic joint symptoms, with adjustment for demographic and clinical factors. Results. The hazard of developing incident knee or hip rOA was 20%-30% higher and of developing progressive knee or hip rOAwas 35%-83% higher among participants with LLI, but results were only statistically significant for progressive knee rOA (adjusted hazard ratio = 1.83, 95% CI 1.10-3.05). The hazards of progressive chronic knee symptoms and incident and progressive chronic hip symptoms were 13%-59% higher among participants with LLI, but were not statistically significant. Conclusion. LLI was associated with progressive knee rOA and was nonsignificantly associated with incident knee or hip rOA and progressive hip rOA, progressive chronic knee symptoms, and incident and progressive chronic hip symptoms. Longer studies may strengthen these associations and help determine whether LLI is a risk factor or marker of these outcomes. The Journal of Rheumatology Copyright © 2010. All rights reserved.
Callahan L.F.,Thurston Arthritis Research Center |
Callahan L.F.,University of North Carolina at Chapel Hill |
Shreffler J.,Thurston Arthritis Research Center |
Siaton B.C.,Duke University |
And 7 more authors.
Arthritis Research and Therapy | Year: 2010
Introduction: Applying a cross-sectional analysis to a sample of 2,627 African-American and Caucasian adults aged ≥ 45 years from the Johnston County Osteoarthritis Project, we studied the association between educational attainment and prevalence of radiographic knee osteoarthritis and symptomatic knee osteoarthritis.Methods: Age- and race-adjusted associations between education and osteoarthritis outcomes were assessed by gender-stratified logistic regression models, with additional models adjusting for body mass index, knee injury, smoking, alcohol use, and occupational factors.Results: In an analysis of all participants, low educational attainment (<12 years) was associated with higher prevalence of four knee osteoarthritis outcomes (unilateral and bilateral radiographic and symptomatic osteoarthritis). Women with low educational attainment had 50% higher odds of having radiographic knee osteoarthritis and 65% higher odds of symptomatic knee osteoarthritis compared with those with higher educational attainment (≥ 12 years), by using fully adjusted models. In the subset of postmenopausal women, these associations tended to be weaker but little affected by adjustment for hormone replacement therapy. Men with low educational attainment had 85% higher odds of having symptomatic knee osteoarthritis by using fully adjusted models, but the association with radiographic knee osteoarthritis was explained by age.Conclusions: After adjustment for known risk factors, educational attainment, as an indicator of socioeconomic status, is associated with symptomatic knee osteoarthritis in both men and women and with radiographic knee osteoarthritis in women. © 2010 Leigh F Callahan et al.; licensee BioMed Central Ltd.
Aslam I.,Northeast Ohio Medical School |
Perjar I.,Northeast Ohio Medical School |
Shi X.A.,University of North Carolina at Chapel Hill |
Renner J.B.,University of North Carolina |
And 4 more authors.
Journal of Rheumatology | Year: 2014
Objective. To determine the associations between joint metabolism biomarkers and hand radiographic osteoarthritis [(rOA), based on Kellgren Lawrence (KL) grade = 2], symptoms, and function. Methods. Cross-sectional data were available for 663 participants (mean age 63 yrs, 63% white, 49% women). Three definitions of hand rOA were considered: (1) a composite measure involving at least 3 hand joints distributed bilaterally with 2 of 3 in the same joint group, including = 1 distal interphalangeal joint, without metacarpophalangeal (MCP) swelling; (2) rOA in at least 1 joint of a group; and (3) number of joints with KL = 2. We assessed hand symptoms and the 15-item Australian Canadian Hand Osteoarthritis Index (AUSCAN; Likert format). We measured serum cartilage oligomeric matrix protein (sCOMP), hyaluronic acid (sHA), carboxy-terminal propeptide of type II collagen, type II collagen degradation product, urinary C-terminal crosslinked telopeptide of type II collagen, and urinary N-terminal crosslinked telopeptide. Linear regression models were performed to assess associations between each biomarker with hand rOA, AUSCAN, and symptoms, adjusting for age, sex, race, current smoking/drinking status, body mass index, and hip and knee rOA. Results. In adjusted analyses, MCP (p < 0.0001) and carpometacarpal rOA (p = 0.003), and a higher number of hand joints with rOA (p = 0.009), were associated with higher levels of sHA. Positive associations were seen between AUSCAN and hand symptoms and levels of sCOMP (p = 0.003) and sHA (p = 0.048). Conclusion. Hand symptoms and higher AUSCAN scores were independently associated with higher levels of both sCOMP and sHA; hand rOA was associated only with sHA levels. © 2014. All rights reserved.
Mielenz T.J.,Columbia University |
Edwards M.C.,Ohio State University |
Callahan L.F.,Thurston Arthritis Research Center
Journal of Aging and Physical Activity | Year: 2011
Benefits of physical activity for those with arthritis are clear, yet physical activity is difficult to initiate and maintain. Self-efficacy is a key modifiable psychosocial determinant of physical activity. This study examined two scales for self-efficacy for exercise behavior (SEEB) to identify their strengths and weaknesses using item response theory (IRT) from community-based randomized controlled trials of physical activity programs in adults with arthritis. The 2 SEEB scales included the 9-item scale by Resnick developed with older adults and the 5-item scale by Marcus developed with employed adults. All IRT analyses were conducted using the graded-response model. IRT assumptions were assessed using both exploratory and confirmatory factor analysis. The IRT analyses indicated that these scales are precise and reliable measures for identifying people with arthritis and low SEEB. The Resnick SEEB scale is slightly more precise at lower levels of self-efficacy in older adults with arthritis. © 2011 Human Kinetics, Inc.
Jordan J.M.,Thurston Arthritis Research Center
Aging Health | Year: 2013
Joanne M Jordan, MD MPH, received her undergraduate education at Cornell University (NY, USA); her medical education at The Johns Hopkins Medical Institutions (MD, USA); and her masters in public health at the University of North Carolina School of Public Health (NC, USA). She received training in internal medicine and subspecialty training in rheumatology and immunology at Duke University Medical Center (NC, USA). She joined the faculty of the Division of Rheumatology, Allergy and Immunology at the University of North Carolina in 1987. She currently is the Chief of the Division of Rheumatology, Allergy and Immunology and the Director of the Thurston Arthritis Research Center at the University of North Carolina. Her research interests are in the epidemiology and genetics of osteoarthritis and disability. She is the principal investigator of the Johnston County Osteoarthritis Project, a large, >20-year, community-based prospective study of individuals aged 45 years and older. The study is the first of its type to include both African-Americans and Caucasians, and is unique in its inclusion of radiographic, serologic, genetic, and physical and functional phenotypic examinations of its participants for multiple chronic diseases. Dr Jordan currently serves as Chair of the US Bone and Joint Initiative's Chronic Osteoarthritis Management Initiative, whose goal is to change the medical paradigm regarding osteoarthritis by incorporating joint health assessment and management into routine medical care. She is the Deputy Editor for Clinical Science of the journal Osteoarthritis and Cartilage and is a member of the Board of Directors of the Osteoarthritis Research Society International. She is the recipient of the Osteoarthritis Research Society International's Clinical Research Award in 2007, the 2009 American College of Rheumatology Award of Distinction in Investigative Mentoring and the 2011 Rural Sociological Society's Distinguished Service to Rural Life Award. © 2013 Future Medicine Ltd.
Commins S.P.,University of North Carolina at Chapel Hill |
Commins S.P.,Thurston Arthritis Research Center |
Kim E.H.,University of North Carolina at Chapel Hill |
Kim E.H.,Thurston Arthritis Research Center |
And 2 more authors.
Current Allergy and Asthma Reports | Year: 2016
Food allergies have increased in prevalence over the past 20 years, now becoming an important public health concern. Although there are no therapies currently available for routine clinical care, recent reports have indicated that immunotherapies targeting the mucosal immune system may be effective. Oral immunotherapy is conducted by administering small, increasing amounts of food allergen; it has shown promise for desensitizing individuals with peanut, egg, or milk allergies. Sublingual immunotherapy also desensitizes allergic patients to foods—two major studies have examined the effects of sublingual immunotherapy in subjects with peanut allergies. We review the complex nature of IgE-mediated food allergies and the therapies being evaluated in clinical trials. We focus on the diagnosis and management of food allergies and investigational therapies. © 2016, Springer Science+Business Media New York.